Repurposing of ribavirin, an antiviral compound used for the treatment of hepatitis C, stems from the discovery that it disrupts eIF4E eukaryotic translation initiation factor that is upregulated in human AML impeding differentiation and leading to transformation [81]. The gene discussed is EIF4E; the disease is acute myeloid leukemia.